Related Experiment Video

Updated: Aug 30, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.2K

Myeloid cell leukemia-1: a formidable barrier to anticancer therapeutics and the quest of targeting it

Prasad Sulkshane1, Tanuja Teni2,3

  • 1Glickman Laboratory, Faculty of Biology, Technion-Israel Institute of Technology, Haifa 3200003, Israel.

Exploration of Targeted Anti-Tumor Therapy
|September 1, 2022
PubMed

Insights

Myeloid cell leukemia-1 (Mcl-1) overexpression drives cancer therapy resistance. This review explores Mcl-1

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • The BCL-2 family regulates apoptosis, crucial for cell survival and death.
  • Overexpression of antiapoptotic BCL-2 members, particularly Mcl-1, is common in cancers.
  • Elevated Mcl-1 levels correlate with therapeutic resistance and poor patient prognosis.

Purpose of the Study:

  • To review mechanisms of Mcl-1 upregulation in tumors.
  • To examine Mcl-1's role in resistance to conventional and targeted therapies.
  • To discuss current and future Mcl-1-targeted therapeutic strategies.

Main Methods:

  • Literature review of studies on Mcl-1 regulation and function.
  • Analysis of data linking Mcl-1 expression to cancer therapy outcomes.
  • Synthesis of information on Mcl-1 inhibitor development.

Main Results:

  • Tumor cells employ diverse strategies to sustain high Mcl-1 levels.
  • High Mcl-1 expression confers resistance to various cancer treatments.
  • Mcl-1 is a validated therapeutic target in hematological malignancies and solid tumors.

Conclusions:

  • Targeting Mcl-1 is a promising strategy to overcome cancer therapy resistance.
  • Developing effective and selective Mcl-1 inhibitors presents challenges.
  • Further research is needed to optimize Mcl-1-targeted therapies for improved patient outcomes.
Keywords:
B cell lymphoma-2Bcl-2 homology 3 mimeticMyeloid cell leukemia-1mitochondrial outer membrane permeabilizationmyeloid cell leukemia-1 inhibitortherapy resistance

More Related Videos

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation09:09

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation

Published on: November 10, 2017

8.4K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K